Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

NCT03249714 ·Status: COMPLETED ·Phase: PHASE2

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

NCT05171972 ·Status: COMPLETED

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

NCT04788615 ·Status: COMPLETED ·Phase: PHASE3

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

NCT05199571 ·Status: COMPLETED ·Phase: PHASE4

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

NCT06854341 ·Status: COMPLETED

A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab

NCT06460324 ·Status: COMPLETED

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

NCT05334472 ·Status: COMPLETED

The 'Wearing Off' Effect of DMT

NCT05627271 ·Status: COMPLETED

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

NCT06167642 ·Status: ENROLLING_BY_INVITATION

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

NCT02792231 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

NCT02792218 ·Status: COMPLETED ·Phase: PHASE3

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

NCT04486716 ·Status: COMPLETED ·Phase: PHASE3

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

NCT04510220 ·Status: COMPLETED ·Phase: PHASE3

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

NCT00640328 ·Status: COMPLETED ·Phase: PHASE2

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

NCT00910598 ·Status: UNKNOWN ·Phase: PHASE4

Characterizing the Use of Ofatumumab in a Real World Setting

NCT05090033 ·Status: COMPLETED

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

NCT05090371 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04847596 ·Status: COMPLETED

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04878211 ·Status: TERMINATED ·Phase: PHASE4

WOE of Anti-CD20 Therapies

NCT06121349 ·Status: COMPLETED

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

NCT06251986 ·Status: COMPLETED

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study

NCT05285904 ·Status: COMPLETED

Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

NCT05266469 ·Status: COMPLETED

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

NCT04676555 ·Status: COMPLETED